Search results for Merck

Merck completes purchase of Terns Pharmaceuticals Inc.

Merck & Co. said on May 5 that it has completed the acquisition of Terns Pharmaceuticals Inc., a drug maker from Foster City, Calif., for $6.7 billion in a deal that brings pro...

Merck initiates Phase 2b/3 trial for treatment of age-related macular degeneration

Rahway-based Merck announced the initiation of a pivotal Phase 2b/3 trial evaluating MK-8748 (also known as Tiespectus, EYE201). It is a novel investigational bispecific antibody t...

Merck KGaA 2026 Q1 - Results - Earnings Call Presentation

At ASCO, Merck makes case for a ‘cornerstone’ cancer drug

Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.

Merck adds to pharma’s AI push; Roche details MS drug results

Merck is making a $1 billion investment in a deal with Google Cloud. Elsewhere, Roche pitched its case for a closely watched multiple sclerosis pill and Arcus and Gilead are ending...

Merck KGaA: Diversified Innovation At An Attractive Valuation

Analyst Reinstates Merck (MRK) with ‘Neutral’ Rating, $125 Price Target

Merck KGaA (MKKGY) Presents at BNP Paribas Exane Healthcare Conference - Slideshow

Merck ADC, licensed from China, hits mark in first big global trial

The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next deca...

Merck inks Keytruda supply pact to support Exelixis’ colorectal cancer trial

Exelixis has secured supplies of subcutaneous Keytruda from Merck & Co. for a planned phase 3 study, completing the trio of contributors needed to run the colorectal cancer tri...

How Merck turned its wonder drug into a blockbuster — and priced out cancer patients worldwide

The pharmaceutical giant has built a fortress of patents, traded in secrecy and relentlessly lobbied to guard its revenue kingpin Keytruda.

<![CDATA[Eli Lilly Enters $7 Billion Agreement to Acquire Kelonia Therapeutics ]]>

Pharmabranche: Merck setzt auf Urgestein: Kai Beckmann übernimmt Chefposten

None

<![CDATA[Pharma M&A Roundup: IMG Pharma Acquires Matsumoto Pharmaceutical, Sun Pharma Acquires Organon ]]>

<![CDATA[Boehringer Ingelheim Expands Immunology Pipeline With Preclinical Antibody Licensing Deal]]>

<![CDATA[Teva Enters $900 Million Agreement to Acquire Emalex]]>

Merck Wins First Trial Over Cosmetic Talc Products Dr. Scholl's, Lotrimin

An Illinois jury in Cook County Circuit Court handed Merck a defense verdict on April 17 after fewer than two hours of deliberations.       

<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Acquires Kelonia Therapeutics]]>

<![CDATA[Pharma M&A Roundup: Bayer to Acquire Perfuse Therapeutics, Madrigal Enters Licensing Agreement for ARO-P...

<![CDATA[Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio]]>

Merck goes with Google for AI push, striking enterprise partnership worth up to $1B

Amid industry layoffs and M&A headlines, Big Pharma's embrace of AI is gaining more steam.

Merck shares are forming a bullish chart pattern, and a breakout could be on the horizon

The pharmaceutical giant is a standout performer within the health-care sector, and the stock could be poised for a big jump.

<![CDATA[Eli Lilly Enters Three Separate Acquisitions Totaling $3.83 Billion ]]>

Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plans

More than a year after licensing its PD-1xVEGF bispecific, Merck & Co. has finally unveiled the first clinical data from the antibody. The results suggest the drug boasts simil...